besthealtharticle.com
Home »
Many people think of new medicines as bullets, and in the pharmaceutical industry, frequently used terms like “targets” and “hits” reinforce that idea. Immuneering co-founder and CEO Ben Zeskind ’03, Ph.D. ’06 prefers a different analogy. His company, which specializes in bioinformatics and computational biology, sees many effective drugs more like noise-canceling headphones. Rather than […]
A new preclinical study by University at Buffalo researchers reveals the genetic basis of relapse, one of the most detrimental but poorly understood behaviors related to addiction. Craig Werner, Ph.D., is first author on a paper published Oct. 9 in Science Advances that demonstrates how prolonged abstinence after cocaine use drives gene changes that promote […]
The cover for issue 55 of Oncotarget features Figure 3, “Romidepsin exhibits anti-tumor effect in xenograft model of DDLPS,” by Seligson, et al. Here the researchers present in silico, in vitro, and mouse xenograft studies that suggest that specifically targeting HDAC2 reduces MDM2 expression and has anti-tumor affects in DDLPS. In a murine DDLPS xenograft […]
Approximately 98 percent of the human genome is made up of noncoding DNA, including enhancers, promoters, and other elements that regulate gene activity. The methods for studying these regions tend to be expensive, labor-intensive, and largely low-throughput. To really understand the functional geography of the noncoding genome, however, researchers need a way to isolate and […]
Genome editing technology is helping A*STAR scientists unravel how the Influenza A virus (IAV) exploits human anti-viral responses. IAV remains a key challenge for global health resources, not least because of wide variations in symptom severity experienced by different people, even when they are infected by the same strain. This implies that there are host […]
Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity. A new study by Boston University School of Medicine (BUSM) researchers suggests that use of HIV RNA expression inhibitors as adjunct therapy might diminish atypical inflammation and restore immune function in HIV-infected individuals […]